DPP-4 inhibitor, which is one of the incretin-based therapies that increase the concentration of circulating GLP-1, has been frequently used for the treatment of T2D because of its relatively low risk of inducing hypoglycemia [25]. Here, DPP4 is linked to Hypoglycemia.